https://www.alkermes.com/
Alkermes – A Global Biopharmaceutical Company
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the field of neuroscience.
a globalalkermesbiopharmaceuticalcompany
https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2020-and-provides-financial-expectations-for-2021-301226495.html
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2020 and provided financial expectations...
https://www.fool.com/earnings/call-transcripts/2018/04/27/alkermes-alks-q1-2018-earnings-conference-call-tra.aspx
Alkermes (ALKS) Q1 2018 Earnings Conference Call Transcript | The Motley Fool
Apr 27, 2018 - ALKS earnings call for the period ending March 31, 2018.
earnings conferencecall transcriptthe motleyalkermesalks
https://www.businesswire.com/news/home/20260416521284/en/Alkermes-to-Present-Additional-Data-From-Vibrance-1-Phase-2-Study-of-Alixorexton-in-Patients-with-Narcolepsy-Type-1-at-the-American-Academy-of-Neurology-AAN-2026-Annual-Meeting
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with...
Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy ty...
https://www.prnewswire.com/news/alkermes-plc/?page=9&pagesize=25
Alkermes plc News and Press Releases | PR Newswire
news and press releasesalkermesplcnewswire
https://www.prnewswire.com/news-releases/research-reports-coverage-on-drug-delivery-stocks----valeant-pharma-delcath-systems-alkermes-and-adamis-pharma-625268623.html
Research Reports Coverage on Drug Delivery Stocks -- Valeant Pharma, Delcath Systems, Alkermes, and...
/PRNewswire/ -- This morning, Stock-Callers.com takes a closer look at Valeant Pharmaceuticals International Inc. (NYSE: VRX), Delcath Systems Inc. (NASDAQ:...
https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-40th-annual-jp-morgan-healthcare-conference-301454212.html
Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at...
https://www.businesswire.com/news/home/20260401025174/en/Alkermes-Announces-Initiation-of-Phase-3-Brilliance-Studies-Evaluating-Alixorexton-for-the-Treatment-of-Narcolepsy-Type-1-and-Type-2?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the...
Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton com...
https://www.benzinga.com/pre-market-outlook/21/09/22777110/12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Alkermes (NASDAQ:ALKS), Assembly...
https://www.prnewswire.com/news-releases/alkermes-to-present-data-on-nemvaleukin-alfa-at-the-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium-301461525.html
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel,...
https://www.prnewswire.com/news-releases/alkermes-to-report-first-quarter-financial-results-on-april-27-2022-301529145.html
Alkermes to Report First Quarter Financial Results on April 27, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 27, 2022...
to reportfirst quarterfinancial resultsalkermes
https://adisinsight.springer.com/patents/800033484
Aripiprazole lauroxil - Alkermes - AdisInsight
aripiprazolealkermesadisinsight
https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-svb-leerink-10th-annual-global-healthcare-conference-301231128.html
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare...
take part
https://www.prnewswire.com/news-releases/6-3-billion-growth-in-addiction-therapeutics-market-during-2021-2025--featuring-alkermes-plc-and-emergent-biosolutions-inc-among-others--technavio-301234230.html
$6.3 Billion Growth in Addiction Therapeutics Market During 2021-2025 | Featuring Alkermes Plc and...
/PRNewswire/ -- Amid the COVID-19 pandemic, the global addiction therapeutics market registered a YOY growth of 5.7% in 2020 and the market is estimated to...
https://ec2-13-251-157-120.ap-southeast-1.compute.amazonaws.com/flash-news/earnings-call-alkermes-plc-reports-solid-q3-growth-eyes-future-expansion/
Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Trade Savi
Oct 25, 2024 - Alkermes Plc reported Q3 2024 results with $378.1 million revenue, an 18% increase, focusing on profitability and proprietary products amid expected EBITDA...
https://fast.wistia.net/embed/iframe/7ebmnhwmcu?seo=true&videoFoam=true
Patient-Inspired Drug Development at Alkermes
drug developmentpatientinspiredalkermes
https://www.prnewswire.com/news-releases/alkermes-announces-strategic-value-enhancement-plan-and-continued-board-refreshment-301190261.html
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and...
strategic valuealkermesannouncesenhancementplan
https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-25-2023-301960854.html
Alkermes to Report Third Quarter Financial Results on October 25, 2023
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023...
to reportthird quarterfinancial resultsalkermes
https://www.fool.com/investing/general/2014/07/22/is-alkermes-plc-stock-undervalued.aspx
Is Alkermes plc Stock Undervalued? | The Motley Fool
Jul 22, 2014 - Strong science and underserved markets can fuel further gains from this delivery-focused biopharma
the motleyalkermesplcstockundervalued
https://www.prnewswire.com/news-releases/trading-in-alkermes-ordinary-shares-halted-today-301149207.html
Trading in Alkermes Ordinary Shares Halted Today
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of...
ordinary sharestradingalkermestoday
https://www.prnewswire.com/news/alkermes-plc/?page=11&pagesize=25
Alkermes plc News and Press Releases | PR Newswire
news and press releasesalkermesplcnewswire